Tariffs are back. What does it mean now for pharma?

While the Trump administration has again levied large new tariffs, drugmakers willing to make deals could gain some relief.

By Kelly Bilodeau • April 6, 2026

How Trump’s war in Iran is scrambling pharma’s shipping options

A blockade at one of the world’s largest shipping lanes could shape the way pharma companies think about manufacturing and distribution.

By Michael Gibney • April 2, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Lilly’s manufacturing bet; hints of a biotech revival

Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.

By PharmaVoice Staff • March 20, 2026

Operating a new standard for life-saving pharmaceutical logistics

Lowering risk and tightening temperature control for today’s complex pharmaceutical logistics.

Feb. 23, 2026

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.

By Alexandra Pecci • Jan. 20, 2026

Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian

In this Q&A discover how DAR-T, a CAR-T platform, addresses challenges in cell therapy manufacturing.

By Nicholas Kirian • Dec. 1, 2025

4 takeaways from pharma’s manufacturing boom

As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

By Alexandra Pecci • Nov. 25, 2025

Why a treatment older than the FDA is getting new regulatory scrutiny

MAHA-aligned patients and providers are pushing back to ensure access to an animal-derived thyroid hormone treatment.

By Kelly Bilodeau • Oct. 20, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Updated Jan. 26, 2026

In cell therapy, cost is a hot issue. The industry might need a cold solution.

The logistical linchpin of cryopreservation could make a challenging space more accessible.

By Michael Gibney • Aug. 19, 2025

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole. 

By Amy Baxter • Aug. 18, 2025

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

By Michael Gibney • Aug. 12, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Pharma’s turbo spending spree on US manufacturing

The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.

By Meagan Parrish • July 24, 2025

Development of flexible assembly and packaging line to support clinical volumes of pens, autoinjectors and safety devices used for drug delivery

West’s new flexible line for pens and autoinjectors, launching Q1 2026, will streamline assembly, labeling, packaging and testing for clinical volumes and drive cost efficiency.

By Madhu Raghunathan, Sr. Director, Business Development and Market Strategy, West Pharmaceutical Services • July 21, 2025

Need a DTC platform? Here’s how one company built its own.

Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. 

By Amy Baxter • July 14, 2025

Trump says ‘very high’ pharmaceutical tariffs coming soon

While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.

By Phil Neuffer • July 9, 2025

How integrated data systems enhance clinical development and manufacturing

How CDMOs are adapting to the surge in demand by committing to digital transformation.

June 16, 2025

Tracking a moving target: Drugmakers brace for a looming tariff impact

With policies in flux, companies seek to be proactive and understand their supply chain.

By Kelly Bilodeau • May 19, 2025

Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

By Alexandra Pecci • April 16, 2025

Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model

Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.

By Michael Gibney • April 14, 2025

Pharma’s US manufacturing moment: Where companies are making the biggest moves

The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.

By Meagan Parrish • April 11, 2025

How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025